PA5-69304

antibody from Invitrogen Antibodies

Targeting: TM6SF2 Lpr4

Western blot (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-69304

Provider

Invitrogen Antibodies

Product name

TM6SF2 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

This target displays homology in the following species: Cow: 93%; Dog: 100%; Guinea Pig: 100%; Horse: 100%; Human: 100%; Mouse: 100%; Rabbit: 75%; Rat: 100%

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

0.5 mg/mL

Storage

-20° C, Avoid Freeze/Thaw Cycles

References

Submitted references

TM6SF2/PNPLA3/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models.

Longo M, Meroni M, Paolini E, Erconi V, Carli F, Fortunato F, Ronchi D, Piciotti R, Sabatini S, Macchi C, Alisi A, Miele L, Soardo G, Comi GP, Valenti L, Ruscica M, Fracanzani AL, Gastaldelli A, Dongiovanni P
Cellular and molecular gastroenterology and hepatology 2022;13(3):759-788

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 13 Recovery of metabolic and carcinogenic anomalies upon MBOAT7 and/or TM6SF2 overexpression. ( A and B ) The mRNA expression of MBOAT7 and TM6SF2 was evaluated by reverse-transcription quantitative PCR and normalized to the beta-actin housekeeping gene. The protein levels of MBOAT7 and TM6SF2 tagged with GFP (MBOAT7-GFP and TM6SF2-GFP) were assessed by Western blot and normalized to the vinculin housekeeping gene. ( C ) LD accumulation was assessed in MBOAT7 -/- TM6SF2 -/- , MBOAT7 +/+ TM6SF2 -/- , MBOAT7 -/- TM6SF2 +/+ , and MBOAT7 +/+ TM6SF2 +/+ by ORO staining (magnification, 630x). ( D ) The expression of ATF4 and ATF6 was evaluated by reverse-transcription quantitative PCR and normalized to the beta-actin housekeeping gene. ( E ) The proliferation rate was examined through MTS assay for 0, 24, 48, 72 hours and 1 week (lambda = 490 nm). ( F ) Representative images of wound healing assay were acquired at 0, 24 and 48 hours (magnification, 100x). The dotted lines indicate the scratch width. At least 3 independent experiments were conducted. For bar graphs, data are expressed as means and SE. Adjusted * P < .05 and ** P < .01 vs MBOAT7 -/- TM6SF2 -/- .

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 2 CRISPR/Cas9-mediated TM6SF2 ablation in HepG2 cells. ( A ) Schematic representation of the TM6SF2 sequence (gene ID: 53345; referred to as transcript variant 1: NM_001001524.3) highlighted the same clonal Cas9-induced indel mutations in both TM6SF2 -/- and MBOAT7 -/- TM6SF2 -/- clones (blue) of 202 nucleotides (Delta202). The Cas9 cutting site is indicated by the symbol ""|"" (red), and the transcription start site (ATG) of the protein coding sequence (NP_001001524.2) is shown in green. ( B ) mRNA and protein expression of TM6SF2 was evaluated through reverse-transcription quantitative PCR and Western blot, respectively. TM6SF2 reduction was detected in TM6SF2 -/- and MBOAT7 -/ - TM6SF2 -/- cells. ( C ) MBOAT7 mRNA and protein levels were lower in MBOAT7 -/- and MBOAT7 -/- TM6SF2 -/- cells compared with Cas9 + and TM6SF2 -/- cells. ( D ) ApoB protein was assessed in cell supernatants by Western blot and normalized to the entire lane of the Ponceau stain. Either TM6SF2 -/- or MBOAT7 -/- TM6SF2 -/- showed low ApoB levels. ( E ) TAG-rich lipoprotein secretion was measured in cell supernatants and normalized to levels of total cholesterol by using the Cholesterol Colorimetric Assay Kit-HDL and LDL/VLDL (Abcam). Both TM6SF2 -/- and MBOAT7 -/- TM6SF2 -/- dampened TAG-rich lipoprotein release. Data were normalized to the beta-actin housekeeping gene for reverse-transcription quantitative PCR and Western blot and they are expressed as means and SE. At least 3 independent exp